Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merus NV MRUS

Healthcare Biotechnology
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's... see more

Recent & Breaking News (NDAQ:MRUS)

Merus Announces Chief Executive Officer Transition

GlobeNewswire December 16, 2019

Merus Announces Chief Executive Officer Transition

Thomson Reuters ONE December 16, 2019

Merus Announces Financial Results for the Third Quarter 2019 and Provides Business Update

GlobeNewswire November 12, 2019

Merus Announces Pricing of Public Offering of Common Shares

Thomson Reuters ONE November 5, 2019

Merus Announces Pricing of Public Offering of Common Shares

GlobeNewswire November 5, 2019

Merus N.V. Announces Proposed Underwritten Public Offering of Common Shares

GlobeNewswire November 4, 2019

Merus N.V. Announces Proposed Underwritten Public Offering of Common Shares

Thomson Reuters ONE November 4, 2019

Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions

Thomson Reuters ONE October 27, 2019

Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions

GlobeNewswire October 27, 2019

Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Thomson Reuters ONE October 25, 2019

Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire October 25, 2019

Merus Announces Financial Results for the Second Quarter 2019 and Provides Business Update

GlobeNewswire August 19, 2019

Merus to Present at the Jefferies 2019 Healthcare Conference

GlobeNewswire June 3, 2019

Merus to Present at the Jefferies 2019 Healthcare Conference

Thomson Reuters ONE June 3, 2019

Merus Announces Financial Results for the First Quarter 2019 and Provides Business Update

GlobeNewswire May 30, 2019

Merus Announces Financial Results for the First Quarter 2019 and Provides Business Update

Thomson Reuters ONE May 30, 2019

Merus Announces 2019 Annual General Meeting of Shareholders

GlobeNewswire May 23, 2019

Merus Announces 2019 Annual General Meeting of Shareholders

Thomson Reuters ONE May 23, 2019

Merus to Present at the RBC Capital Markets 2019 Healthcare Conference

GlobeNewswire May 20, 2019

Merus to Present at the RBC Capital Markets 2019 Healthcare Conference

Thomson Reuters ONE May 20, 2019